nVent Electric (NYSE:NVT) had its target price increased by research analysts at Barclays from $38.00 to $39.00 in a report issued on Tuesday, The Fly reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price objective points to a potential upside of 35.46% from the company’s previous close.
NVT has been the topic of a number of other research reports. Zacks Investment Research downgraded shares of nVent Electric from a “hold” rating to a “sell” rating in a report on Friday, February 5th. Royal Bank of Canada boosted their price target on nVent Electric from $27.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, March 4th. Wolfe Research raised nVent Electric from a “peer perform” rating to an “outperform” rating and increased their price objective for the company from $24.00 to $31.00 in a report on Tuesday, December 8th. KeyCorp raised their price objective on nVent Electric from $28.00 to $31.00 and gave the company an “overweight” rating in a research note on Thursday, March 11th. Finally, Rosenblatt Securities decreased their target price on nVent Electric from $32.00 to $31.00 and set a “buy” rating for the company in a research report on Wednesday, February 10th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $30.33.
NVT opened at $28.79 on Tuesday. The company has a market capitalization of $4.84 billion, a PE ratio of -99.28 and a beta of 1.53. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.99 and a quick ratio of 1.41. nVent Electric has a fifty-two week low of $15.60 and a fifty-two week high of $29.94. The business has a 50-day moving average of $27.46 and a 200-day moving average of $23.02.
nVent Electric (NYSE:NVT) last released its quarterly earnings data on Monday, February 8th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.01. The firm had revenue of $521.00 million for the quarter, compared to the consensus estimate of $515.62 million. nVent Electric had a positive return on equity of 10.35% and a negative net margin of 2.39%. The firm’s revenue was down 8.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.47 earnings per share. On average, equities research analysts expect that nVent Electric will post 1.49 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVT. River & Mercantile Asset Management LLP acquired a new position in shares of nVent Electric during the fourth quarter worth approximately $6,024,000. Strs Ohio boosted its holdings in nVent Electric by 13.0% in the 3rd quarter. Strs Ohio now owns 62,617 shares of the company’s stock valued at $1,107,000 after purchasing an additional 7,227 shares during the period. Nuveen Asset Management LLC grew its position in nVent Electric by 273.2% in the 4th quarter. Nuveen Asset Management LLC now owns 2,307,193 shares of the company’s stock worth $53,734,000 after purchasing an additional 1,688,904 shares during the last quarter. Ellevest Inc. raised its holdings in nVent Electric by 48.2% in the 4th quarter. Ellevest Inc. now owns 5,745 shares of the company’s stock valued at $134,000 after acquiring an additional 1,869 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of nVent Electric by 7.2% in the fourth quarter. Rhumbline Advisers now owns 459,468 shares of the company’s stock valued at $10,701,000 after purchasing an additional 30,682 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.
nVent Electric Company Profile
nVent Electric plc designs, manufactures, markets, installs, and services electrical connection and protection products in the United States, Canada, Western and Eastern Europe included in European Union, China, Eastern Europe not included in European Union, Latin America, the Middle East, Southeast Asia, Australia, and Japan.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
We all knew that traditional healthcare services were disrupted in 2020. The patient-doctor relationship went virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have that option available to them. And even local pharmacies took on a new e-commerce role as curbside pickup or home delivery of prescription medication became the norm.
Not surprisingly healthcare stocks were battered last year. Overall, the sector was down 11%, far below the S&P 500 Index that climbed over 15%.
However, the market is always forward-looking with a particular eye towards innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late-stage trials for drugs that can deliver breakthrough results for conditions that continue to plague our world.
That’s the focus of this presentation. We’ve identified 7 healthcare stocks that are delivering innovative ideas that will help deliver better patient outcomes. And in some cases will revolutionize medicine altogether. These are also the stocks that analysts have their eye on.